About Activate Immunotherapy
Activate Immunotherapy (formerly NovaRx) is a clinical-stage immuno-oncology company based in San Diego, California. Activate utilizes a novel approach for activating the body's immune system to recognize and destroy cancer cells. The company's most advanced immunotherapy, Lucanix, has been tested in late stage clinical trials as a treatment for non-small cell lung cancer (NSCLC), the largest cancer indication in the world. Lucanix has promising Phase 2 and Phase 3 data. In Lucanix's Phase 2 trial, the company demonstrated a significant improvement in survival for NSCLC patients. NovaRx completed a 532 patient Phase 3 study in early 2013. While the Phase 3 study missed the statistical endpoint for approval, survival benefits were shown if non United States clinical sites were excluded, particularly with patients who started Lucanix treatment within 12 weeks of chemotherapy and/or patients with prior chemotherapy and radiation therapy. Activate's proprietary platform technology is applicable to other solid tumors.
Missing: Activate Immunotherapy's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Activate Immunotherapy's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Activate Immunotherapy
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Activate Immunotherapy is included in 2 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Latest Activate Immunotherapy News
Oct 7, 2016
Activate Immunotherapy Terminates Financing Agreement Former employees of Bruce Edward Cahill, a Trustee of University of California at Irvine, have sued the Laguna Beach native for alleged sexual harassment and wrongful termination. The Complaint alleges that this is not the first allegation of sexual misconduct against Cahill (Orange County Superior Court Case 02CC17434), nor is it the first time former Cahill employees have faced off against the businessman (Orange County Superior Court Case 02CC17434, San Diego County Superior Court 37-2014-00019922-CU-PT-CTL, and Orange County Superior Court Case 30-2012-00610130-CU-BT-CJC). According to the Employees’ lawsuit, filed in the United States Federal Court in the Central District of California, Pharma Pak CEO and President Cahill, along with fellow partners Shane Ryan Scott, Ronald Ventura Franco, and Gregory David Cullen, allegedly conspired to wrongfully terminate certain employees to cover CEO Cahill’s actions. The employees had cooperated with an Irvine Police Department investigation into CEO Cahill’s alleged illegal Schedule 1 Drug manufacturing operations, as the employees detail in their complaint filed in Federal Court (case number 8:16-cv-00686-AG-DFM). Former Vice President of Sales Olivia Karpinski also alleges sexual harassment and sexual assault by Cahill. It is alleged in the Complaint that in February of 2016, the Irvine Police Department was notified of the illegal THC (tetrahydrocannabinol) in the Pharma Pak, Inc. manufacturing facility. A subsequent investigation was opened, headed by Detective Grange, under case number 16-3257. The THC, allegedly belonging to Dr. Ludwig Jan Weimann, Cahill’s Chief Science Officer, was confiscated and a police investigation opened. When Cahill learned of this, the complaint alleges, he fired only those employees involved in the investigation. Documents entered into as Exhibits in the Federal Court (case 8:16-cv-00686-AG-DFM) by the employees show that Weimann and others not involved in the investigation are still employed by Cahill. Karpinski and the employees allege in the complaint that their termination was a result of cooperation with the Irvine Police Department. The employees further allege attempts by Cahill and his private investigator Cameron Jackson to intimidate employees. In their complaint the employees state that both men attempted to prevent further investigation by the Irvine Police Department into Cahill’s activities by allegedly threatening employees as they left the facility on the day of their termination. Karpinski and the other defendants have filed over 600 pages of exhibits with the Court as part of their response and subsequent cross-complaint in this lawsuit. All documents are available via the Court’s public website at PACER.gov. The former employees have filed their case in the United States Federal Court, Central District of California, Case Number 8:16-cv-00686-AG-DFM. The Irvine Police Department ongoing investigation into the Schedule 1 Drugs found at Cahill’s Irvine manufacturing facility is Case Number 16-3257, headed by Detective Scott Grange. For the original version on PRWeb visit: http://www.prweb.com/releases/2016/10/prweb13743738.htm
Activate Immunotherapy Frequently Asked Questions (FAQ)
When was Activate Immunotherapy founded?
Activate Immunotherapy was founded in 1997.
Where is Activate Immunotherapy's headquarters?
Activate Immunotherapy's headquarters is located at 8395 Camino Santa Fe Drive, San Diego.
What is Activate Immunotherapy's latest funding round?
Activate Immunotherapy's latest funding round is Unattributed.
Who are the investors of Activate Immunotherapy?
Investors of Activate Immunotherapy include David Murdock.
Who are Activate Immunotherapy's competitors?
Competitors of Activate Immunotherapy include Esperance Pharmaceuticals, Immune Design, Veracyte, SpiroGen, Amplimmune Immunology and 13 more.
Compare Activate Immunotherapy to Competitors
ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.
Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..
NanoMedex uses patented formulation strategies to dissolve drugs in water that are only soluble in fats or lipids. Once dissolved in water, these drugs can be administrated intravenously. In hospitals, intravenous administration is preferred by older patients to eliminate swallowing, by physicians to increase certainty that the correct drug dose is given, and by health care providers to ensure that Medicare reimburses 100 percent of costs (versus 50 percent for oral administration).
Bioceramic Therapeutics Limited is developing new kinds of material that help the body heal itself. The aim is to assist patients, especially the elderly, for whom normal tissue repair mechanisms do not result in possible medical outcomes. Such patients may have fractures or osteoporosis, need orthopedic or periodontal implants or have a condition that has damaged their bones.
NellOne Therapeutics is a regenerative-medicine spinout of the U.S. Department of Energy's Oak Ridge National Laboratory (ORNL). The start-up, in the proof-of-efficacy stage, is dedicated to exploring the creation of protein therapeutics for their potential in restoring tissue mass andfunction in patients recovering from heart attacks. Current therapeutic approaches, such as those based on stem cells, have shown the potential to restore tissue mass, but with only limited recovery of function. General Partner Tracy Warren is acting CEO and a member of the Board of Directors. (See deal announcement.)
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.